A year after advanced therapy, 54-year-old Leukaemia patient's life returns to normal

For decades, relapsed leukaemia in adults carried a sobering prognosis. Patients who failed first-line treatment or suffered recurrence had few meaningful options, and the conversation too often shifted from cure to management. That is no longer an acceptable endpoint. CAR T-cell therapy, combined immunotherapy, and precision-driven treatment sequencing have fundamentally changed what is achievable in adult blood cancer care.

Sunita Rao (name changed), a 54-year-old female, was diagnosed with Philadelphia chromosome-negative B-cell Acute Lymphoblastic Leukaemia (B-ALL), an aggressive form of leukaemia known to pose significant clinical challenges despite standard treatment approaches. Her situation was made considerably harder by a severe active infection at presentation, which significantly limited the treatment options available at the outset.

She was started on immunotherapy but relapsed during treatment, adding another layer of difficulty to an already demanding case. The team at the hospital adopted a considered, stepwise approach: a combination of chemotherapy and immunotherapy to bring the disease back under control, followed by CAR T-cell therapy once the clinical conditions allowed it.

The path was not straightforward. Multiple secondary infections emerged during treatment, each requiring immediate response and careful management. Sustained supportive care and intensive monitoring were not secondary considerations; they were as central to the outcome as the therapy itself.

One year after completing advanced treatment, Sunita is in complete remission. She has returned to her daily routine and reports a good quality of life.

"The most important work happens before the therapy starts," said Dr Punit Jain, Lead Consultant Haematology, Haemato Oncology & Program Coordinator Bone Marrow Transplant & CAR T-cell Therapy, Apollo Hospitals Navi Mumbai.
He added, "We must be honest with patients about the struggle ahead. Many adults are told they have no options left, and that belief is a heavy burden to carry. Sunita’s recovery shows that the timing of each step is vital. You cannot just use CAR T-cell therapy and hope for the best. You have to prepare the patient’s body through intense supportive care. That is how you win. Even with the best available therapies, the disease may sometimes recur. However, CAR T-cell therapy offers renewed hope for patients with B-cell lymphomas and leukaemias that are refractory to conventional treatments."

Sunita's recovery reflects a broader shift in how relapsed adult leukaemia is now being approached. The change is not purely technological; it is a change in clinical conviction. Where palliation was once the expected course for patients who relapsed, curative intent is today a realistic, achievable goal. Reaching it demands advanced therapies, experienced multidisciplinary teams, and the institutional commitment to support patients through a long and demanding treatment journey. Apollo Hospitals remains firmly dedicated to that standard, for every patient, however difficult the path ahead.